Effects of propionyl-L-carnitine in chronically hypoperfused ('hibernating') myocardium

H. Bolukoglu, A. M. Eggleston, R. Subramanian, S. H. Nellis, A. J. Liedtke

Research output: Contribution to journalArticle

Abstract

The purpose of this report was to test the effects of systemic treatment with propionyl-L-carnitine in a new model of chronically hypoperfused ('hibernating') myocardium. Adolescent swine were instrumented to undergo a period of mild partial coronary constriction for 1 week (50% reduction of the maximum phasic flow velocity in the anterior descending coronary artery). This reduced regional mechanical function by 56%. The system satisfied criteria defining 'hibernating' myocardium, in that the chronic hypoperfusion did not produce massive tissue necrosis and that the reduction in regional contraction remained responsive to inotropic stimulation. Treatment with 50 mg/kg propionyl-L-carnitine by mouth twice daily for 1 week significantly (p < 0.0005) increased concentrations of free and total carnitine in the myocardial tissue by 39% and 31%, respectively. Treatment with propionyl-L-carnitine did not alter regional systolic shortening in either hibernation or reperfusion for 2 hours, but enhanced one estimate of contractility reserve based on the rate of left ventricular emptying with occlusion of the inferior vena cava. Propionyl-L-carnitine did not reverse the observed impairments in mitochondrial respiration (diminutions in state 3 respiration and the respiratory control ratio), but limited the number of lesions seen on histological examination. Six out of eight placebo hearts showed one or more changes of ischemia, infarction or reperfusion injury, while the same was true in only two out of eight hearts treated with propionyl-L-carnitine (p < 0.003). Carnitine and various analogues have been proposed to benefit ischemic myocardium. The present data suggest that this general sparing effect may also occur with the propionyl derivative in chronically underperfused myocardium.

Original languageEnglish (US)
Pages (from-to)245-255
Number of pages11
JournalCardioscience
Volume2
Issue number4
StatePublished - Dec 1 1991

Fingerprint

propionylcarnitine
Carnitine
Myocardium
Respiration
Hibernation
Inferior Vena Cava
Reperfusion Injury
Constriction
Infarction
Reperfusion
Mouth

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bolukoglu, H., Eggleston, A. M., Subramanian, R., Nellis, S. H., & Liedtke, A. J. (1991). Effects of propionyl-L-carnitine in chronically hypoperfused ('hibernating') myocardium. Cardioscience, 2(4), 245-255.

Effects of propionyl-L-carnitine in chronically hypoperfused ('hibernating') myocardium. / Bolukoglu, H.; Eggleston, A. M.; Subramanian, R.; Nellis, S. H.; Liedtke, A. J.

In: Cardioscience, Vol. 2, No. 4, 01.12.1991, p. 245-255.

Research output: Contribution to journalArticle

Bolukoglu, H, Eggleston, AM, Subramanian, R, Nellis, SH & Liedtke, AJ 1991, 'Effects of propionyl-L-carnitine in chronically hypoperfused ('hibernating') myocardium', Cardioscience, vol. 2, no. 4, pp. 245-255.
Bolukoglu H, Eggleston AM, Subramanian R, Nellis SH, Liedtke AJ. Effects of propionyl-L-carnitine in chronically hypoperfused ('hibernating') myocardium. Cardioscience. 1991 Dec 1;2(4):245-255.
Bolukoglu, H. ; Eggleston, A. M. ; Subramanian, R. ; Nellis, S. H. ; Liedtke, A. J. / Effects of propionyl-L-carnitine in chronically hypoperfused ('hibernating') myocardium. In: Cardioscience. 1991 ; Vol. 2, No. 4. pp. 245-255.
@article{4555f92ca84345fdafb0c6456895a1c9,
title = "Effects of propionyl-L-carnitine in chronically hypoperfused ('hibernating') myocardium",
abstract = "The purpose of this report was to test the effects of systemic treatment with propionyl-L-carnitine in a new model of chronically hypoperfused ('hibernating') myocardium. Adolescent swine were instrumented to undergo a period of mild partial coronary constriction for 1 week (50{\%} reduction of the maximum phasic flow velocity in the anterior descending coronary artery). This reduced regional mechanical function by 56{\%}. The system satisfied criteria defining 'hibernating' myocardium, in that the chronic hypoperfusion did not produce massive tissue necrosis and that the reduction in regional contraction remained responsive to inotropic stimulation. Treatment with 50 mg/kg propionyl-L-carnitine by mouth twice daily for 1 week significantly (p < 0.0005) increased concentrations of free and total carnitine in the myocardial tissue by 39{\%} and 31{\%}, respectively. Treatment with propionyl-L-carnitine did not alter regional systolic shortening in either hibernation or reperfusion for 2 hours, but enhanced one estimate of contractility reserve based on the rate of left ventricular emptying with occlusion of the inferior vena cava. Propionyl-L-carnitine did not reverse the observed impairments in mitochondrial respiration (diminutions in state 3 respiration and the respiratory control ratio), but limited the number of lesions seen on histological examination. Six out of eight placebo hearts showed one or more changes of ischemia, infarction or reperfusion injury, while the same was true in only two out of eight hearts treated with propionyl-L-carnitine (p < 0.003). Carnitine and various analogues have been proposed to benefit ischemic myocardium. The present data suggest that this general sparing effect may also occur with the propionyl derivative in chronically underperfused myocardium.",
author = "H. Bolukoglu and Eggleston, {A. M.} and R. Subramanian and Nellis, {S. H.} and Liedtke, {A. J.}",
year = "1991",
month = "12",
day = "1",
language = "English (US)",
volume = "2",
pages = "245--255",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Effects of propionyl-L-carnitine in chronically hypoperfused ('hibernating') myocardium

AU - Bolukoglu, H.

AU - Eggleston, A. M.

AU - Subramanian, R.

AU - Nellis, S. H.

AU - Liedtke, A. J.

PY - 1991/12/1

Y1 - 1991/12/1

N2 - The purpose of this report was to test the effects of systemic treatment with propionyl-L-carnitine in a new model of chronically hypoperfused ('hibernating') myocardium. Adolescent swine were instrumented to undergo a period of mild partial coronary constriction for 1 week (50% reduction of the maximum phasic flow velocity in the anterior descending coronary artery). This reduced regional mechanical function by 56%. The system satisfied criteria defining 'hibernating' myocardium, in that the chronic hypoperfusion did not produce massive tissue necrosis and that the reduction in regional contraction remained responsive to inotropic stimulation. Treatment with 50 mg/kg propionyl-L-carnitine by mouth twice daily for 1 week significantly (p < 0.0005) increased concentrations of free and total carnitine in the myocardial tissue by 39% and 31%, respectively. Treatment with propionyl-L-carnitine did not alter regional systolic shortening in either hibernation or reperfusion for 2 hours, but enhanced one estimate of contractility reserve based on the rate of left ventricular emptying with occlusion of the inferior vena cava. Propionyl-L-carnitine did not reverse the observed impairments in mitochondrial respiration (diminutions in state 3 respiration and the respiratory control ratio), but limited the number of lesions seen on histological examination. Six out of eight placebo hearts showed one or more changes of ischemia, infarction or reperfusion injury, while the same was true in only two out of eight hearts treated with propionyl-L-carnitine (p < 0.003). Carnitine and various analogues have been proposed to benefit ischemic myocardium. The present data suggest that this general sparing effect may also occur with the propionyl derivative in chronically underperfused myocardium.

AB - The purpose of this report was to test the effects of systemic treatment with propionyl-L-carnitine in a new model of chronically hypoperfused ('hibernating') myocardium. Adolescent swine were instrumented to undergo a period of mild partial coronary constriction for 1 week (50% reduction of the maximum phasic flow velocity in the anterior descending coronary artery). This reduced regional mechanical function by 56%. The system satisfied criteria defining 'hibernating' myocardium, in that the chronic hypoperfusion did not produce massive tissue necrosis and that the reduction in regional contraction remained responsive to inotropic stimulation. Treatment with 50 mg/kg propionyl-L-carnitine by mouth twice daily for 1 week significantly (p < 0.0005) increased concentrations of free and total carnitine in the myocardial tissue by 39% and 31%, respectively. Treatment with propionyl-L-carnitine did not alter regional systolic shortening in either hibernation or reperfusion for 2 hours, but enhanced one estimate of contractility reserve based on the rate of left ventricular emptying with occlusion of the inferior vena cava. Propionyl-L-carnitine did not reverse the observed impairments in mitochondrial respiration (diminutions in state 3 respiration and the respiratory control ratio), but limited the number of lesions seen on histological examination. Six out of eight placebo hearts showed one or more changes of ischemia, infarction or reperfusion injury, while the same was true in only two out of eight hearts treated with propionyl-L-carnitine (p < 0.003). Carnitine and various analogues have been proposed to benefit ischemic myocardium. The present data suggest that this general sparing effect may also occur with the propionyl derivative in chronically underperfused myocardium.

UR - http://www.scopus.com/inward/record.url?scp=0026348272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026348272&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 245

EP - 255

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 4

ER -